Envoyer à un ami

IL-23 inhibitor risankizumab induces remission in Phase II study in patients with ...

- 24 Mai 2016 modifié le 1 Janvier 1970

  • After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn's disease, the majority of whom had previously failed treatment with one or more TNF antagonists, achieved clinical remission with risankizumab compared with placebo1
  • Endoscopic remission was achieved in 15% and 20% of patients receiving 200 mg and 600 mg risankizumab, respectively, compared with three percent of patients receiving placebo after 12 weeks1
  • These results indicate that the selective blockade of IL-23 with risankizumab may be a promising new therapeutic approach for this serious chronic disease and warrants further investigation

(BUSINESS WIRE)-- Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn's disease with investigational biologic, risankizumab (formerly BI 655066), a compound from Boehringer Ingelheim research and recently licensed by AbbVie. ...

Source :